Donepezil did not reduce the rate of institutionalisation or disability in people with mild to moderate Alzheimer's disease: Commentary

Evidence-Based Mental Health

Volumn 7, Issue 4, 2004, Pages 112-

  Standridge, John B ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33144477329     PISSN: 13620347     EISSN: None     Source Type: Journal    
DOI: 10.1136/ebmh.7.4.112     Document Type: Note

References (6)

1. Standridge JB. Pharmacotherapeutic approaches to the treatment of Alzheimer's disease. Clin Ther 2004;26:615-30.
2. Trinh NH, Hoblyn J, Mohanty S, et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003;289:210-16. (Pubitemid 36068709)
3. Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004;63:214-19. (Pubitemid 38971117)
4. Lanctot KL, Herrmann N, Yau KK, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 2003;169:557-64. (Pubitemid 37174596)
5. Birks JS, Harvey R. Donepezil for dementia due to Alzheimer's disease (Cochrane Review). In: The Cochrane Library, Issue 3. Chichester, UK: John Wiley & Sons Ltd, 2004.
6. Cummings JL. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry 2003;11:131-45. (Pubitemid 36254187)